Shares of GENFLEET-B (02595) surged 15.06% in afternoon trading, currently quoted at HK$27.96, with a turnover of HK$40.1055 million.

According to an announcement from the company, it has initiated an overseas Phase II study for GFH375/VS-7375, an oral KRAS G12D inhibitor, targeting KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma (PDAC), with the first patient already enrolled recently. This open-label, multi-center study (TARGET-D 201) is being designed and advanced by GENFLEET's partner Verastem Oncology in the US. It will explore a first-line combination therapy regimen (with cetuximab), as well as monotherapy and later-line combination therapy with cetuximab.

Bank of Communications International issued a research report stating that it maintains its "Buy" investment rating and HK$51 target price for GENFLEET (02595). The bank noted that the overseas clinical development and partnership progress for the KRAS G12D inhibitor are promising. Bank of Communications International believes the excellent preliminary overseas data provides further evidence for VS-7375's best-in-class potential. Verastem is expected to disclose more efficacy data from the TARGET-D 101 study in the second half of 2026, which warrants close attention. Other key overseas catalysts include: 1) Completion of enrollment for the pancreatic cancer and NSCLC monotherapy cohorts and the CRC combination cohort in the TARGET-D 101 study (by end of June); 2) Discussions with the FDA regarding the design of a first-line Phase III study (by end of 2026) and initiation of patient enrollment (in the first half of 2027).